

Zambia SAMIPS cohort study

Gill positivity estimates ratio

SAMIPS Cohort - Zambia

- **Study Design & Cohort**
 - Southern Africa Mother Infant Pertussis Study (SAMIPS) longitudinal birth cohort in Zambia
 - 1981 Mother-infant pairs enrolled at ≈ 1 week of age
 - Followed every 2–3 weeks through 14 weeks post-birth
 - NP sampling at every visit - including baseline, scheduled and unscheduled (resp complaints) visits
 - Infants received scheduled vaccines at 6, 10, and 14 weeks with the pentavalent vaccine
- **Pertussis Case Definitions**
 - The CDC case definition for a laboratory-confirmed pertussis infection can be met in **either** of two ways:
 1. Culture-positive *Bordetella* pertussis with any duration of cough, or
 2. PCR-positive *B. pertussis* plus ≥ 2 weeks of cough together with at least one classic symptom: whooping, paroxysmal cough, apnea, or post-tussive vomiting.
 - A screening definition was developed - an infant presenting with any of the signs or symptoms on our screening form with a positive PCR result.
 - Positive cases were further classified as severe/nonsevere pertussis using the modified perziosi scale

Gill et al, 2016

What is a pertussis positive PCR Test?

The 2016 paper used the following diagnostic algorithm to define PCR positive cases.

- PCR-positive when the IS481 Ct < 35 or
- IS481 Ct fell between 35–40 together with a PTxS1 signal

Supplementary Table 1a. Diagnostic algorithm for interpreting PCR results

| Primer reactions | | | | Interpretation |
|-------------------------|------------|----------|----------|------------------------------------|
| IS481 | PTxS1 | PIS1001* | HIS1001* | |
| Ct<35 | (+) or (-) | NA | NA | <i>B. pertussis</i> |
| 35<=CT<40 | (+) | NA | NA | <i>B. pertussis</i> |
| 35<=Ct<40 | (-) | NA | NA | Indeterminate |
| (+ at any CT value <40) | (-) | (-) | (+) | <i>B. holmesii</i> |
| (-) | (+) | (+) | (-) | <i>B. parapertussis</i> |
| (-) | (-) | (-) | (-) | Non-Bordetella respiratory disease |

IS481

- highly sensitive target
- most common insertion sequence in *B. pertussis*
- multiple copies per genome

PTxS1

- highly specific target
- coding for pertussis toxin
- exists as a single or double copy

Gill et al, 2016 contd.

RESULTS

- 10 positive pertussis cases were identified
- Only 1 infant qualified as “severe pertussis” who was unimmunized and 3 weeks old
- 100% pertussis positive cases were symptomatic
- 0% with severe pertussis in vaccinated while 14% of unvaccinated cases with typical/severe pertussis

| Pertussis + | | N ^a =10 | Typical/Severe (paroxysmal cough >=14d) | Moderate/ Nonsevere | Sx (any) |
|--|--------|--------------------|---|------------------------|----------|
| Vaccinated | | 3 | 0 | 3 (100%) | 3 (100%) |
| Age (m) | 3 - <4 | 3 | 0 | 3 (100%) | 3 (100%) |
| Unvaccinated ¹ (includes not effectively vaccinated) | | 7 | 1 (14%) | 6 (86%) | 7 (100%) |
| Age (m) | 0- <1 | 2 | 1 (50%) | 1 (50%) | 2 (100%) |
| | 1- <2 | 2 | 0 | 2 (100%) | 2 (100%) |
| | 2- <3 | 3 | 0 | 3 (100%) | 3 (100%) |

¹ includes vaccinated children with less than 21 days from last immunization to diagnosis

^a Denominator for Row%

<https://doi.org/10.1093/cid/ciw526>

Table 6. Incidence of Infant Pertussis by Prior Number of Whole-Cell Pertussis Vaccinations

| Immunization Status ^a | No. of Infants | Person-time, months | Incidence Rate per 1000 Person-months ^b |
|----------------------------------|----------------|---------------------|--|
| All pertussis | | | |
| No immunization | 4 | 1882 | 2.1 |
| 1 DTP dose | 4 | 1458 | 2.7 |
| 2 DTP doses | 2 | 914 | 2.2 |
| Nonsevere pertussis | | | |
| No immunization | 3 | 1882 | 1.6 |
| 1 DTP dose | 4 | 1459 | 2.7 |
| 2 DTP doses | 2 | 915 | 2.2 |
| Severe pertussis | | | |
| No immunization | 1 | 1882 | 0.5 |
| 1 DTP dose | 0 | 1463 | 0 |
| 2 DTP doses | 0 | 921 | 0 |

Abbreviation: DTP, diphtheria-tetanus-pertussis vaccine.

^a The final nasopharyngeal swab was obtained at the same visit at which DTP dose 3 was given. Therefore, we have no incidence data after DTP dose 3.

^b In all cases, incidence was calculated allowing for 2 weeks for the infants to respond to the

Gill et al, 2021

A detecting assay is any IS481 qPCR test that produces a measurable fluorescence signal before the assay reaches its maximum number of cycles. In this study every sample was run for 45 PCR cycles;

In 2016 paper,

- Threshold Ct=35
- Pertussis -ive cases: Ct >35

In 2021 analysis,

- Detecting assay: a Ct value ≤ 45 (target DNA detected)
- Non-detecting assay: Ct = 45 (no signal after the full run)

The authors wanted to justify that lab diagnosed testing where only Ct<35 are considered positive for pertussis might not be representative of actual pertussis circulation in the population.

EFI = Evidence of Infection

For every subject

- IS481 PCR Cycle Threshold values for all assays (Ct) arranged from the highest to the lowest
- For every assay, proportion of assays that were as strong or stronger calculated and graphed = RCD (reverse cumulative distribution)
- Geometric mean of the RCD calculated
- $1 - \text{Geometric Mean} = \text{EFI}$

EFI = 0 means all assays were non-detecting NO EVIDENCE

EFI = 1 means repeatedly strong Ct values.

To categorize infection strength, they set a threshold based on the number of detecting assays:

Strong EFI: participants with ≥ 3 detecting assays,

Weak EFI: those with > 0 but < 3 detecting assays

None EFI: those with no detecting assays

Gill et al, 2021

Among infants with strong molecular evidence of infection, the percent asymptomatic or minimally symptomatic was **59% among unvaccinated** and **79% among vaccinated**

(no difference by #doses: 1d: 5/6 = 83.3%, 2d: 20/26 = 76.9%, 3d: 101/128 = 78.9%)

Only one infant presented with classic symptoms of whooping and paroxysmal cough (unvaccinated, 26 days of age).

| Unvaccinated | | | | | | Vaccinated | | | | | | |
|------------------------------|--------------|-------|------------------------------|--------------|-----|------------------------------|-------|--------------|--------------------------------|---------------|------|--|
| | EFI Category | | | | | | | EFI Category | | | | |
| | + Pertussis | | | | | | | + Pertussis | | | | |
| Symptoms | Neg | Weak | Strong | Total+ | Sum | Symptoms | Neg | Weak | Strong | Total+ | Sum | |
| None | 18 | 4 | 2 | 6 | 24 | None | 428 | 89 | 39 | 128 | 556 | |
| Minimal ¹ | 33 | 21 | 8 | | 62 | Minimal ¹ | 279 | 107 | 87 | | 473 | |
| Moderate/Severe ² | 16 | 10 | 7 | 17 | 33 | Moderate/Severe ² | 92 | 46 | 34 | 80 | 172 | |
| Typical (parox.) | | | | 1/52 (1.9%) | | Typical (parox.) | | | | 0/402 (0%) | | |
| Sum | 67 | 35 | 17 | 52 | 119 | Sum | 799 | 242 | 160 | 402 | 1201 | |
| % Asx | | | | 11.5% | | % Asx | | | | 31.8% | | |
| % Asx or mild | | | 10/17= 58.8 | | | % Asx or mild | | | 126/160= 78.8 | | | |
| % mod/sev Sx | 23.9% | 28.6% | 7/17= 41.2% (21.6%-64.0%) | 17/52= 32.7% | | % mod/sev Sx | 11.5% | 19.0% | 34/160= 21.2% (15.6%-28.2%) | 80/402= 19.9% | | |

¹ Minimal symptoms include coryza and/or uncomplicated cough.

² Moderate to severe symptoms include all other pertussis symptoms in the Modified Preziosi Scale.

<https://doi.org/10.7554/eLife.65663>